Publications by authors named "D K Christen"
Article Synopsis
- CD2, CD25, and CD30 expression in extracutaneous mast cells is a minor diagnostic criterion for systemic mastocytosis (SM), as categorized by the World Health Organization and International Consensus Classification.
- A study of 5,034 patients revealed that lower percentages of CD2, CD25, and/or CD30 in mast cells are seen in indolent SM compared to advanced forms like aggressive SM and mast cell leukemia.
- The absence of CD2 in mast cells is linked to significantly lower overall survival and indicates the potential for disease spread outside the bone marrow to organs like the spleen and liver.
BRAF serves as a gatekeeper of the RAS/RAF/MEK/ERK pathway, which plays a crucial role in homeostasis. Since aberrant signalling of this axis contributes to cancer and other diseases, it is tightly regulated by crosstalk with the PI3K/AKT/mTOR pathway and ERK mediated feedback loops. For example, ERK limits BRAF signalling through phosphorylation of multiple residues.
View Article and Find Full Text PDFArticle Synopsis
- * The study analyzes the use of the Papillon device, which delivers low energy X-rays for radiotherapy, allowing dose escalation without harming surrounding tissues.
- * Results from treating 24 patients showed a 96% organ preservation rate and an 8% local relapse rate after a median follow-up of 43 months, with no severe toxicities, indicating Papillon as a promising alternative to surgery.
Article Synopsis
- Hypersensitivity reactions (HR) are common in mastocytosis, a condition analyzed using data from the European Competence Network on Mastocytosis (ECNM), involving 2485 adults.
- About 38.1% of patients reported HR, with Hymenoptera venoms being the primary trigger for cutaneous mastocytosis and indolent systemic mastocytosis, while drug reactions were more common in advanced systemic mastocytosis.
- Key risk factors for HR include lower tryptase levels, minimal mast cell infiltration in bone marrow, and a diagnosis of indolent systemic mastocytosis, with new reactions occurring in 4.8% of patients over four years.
Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter.
View Article and Find Full Text PDF